ASCO 2026 | Adjuvant cemiplimab in high-risk CSCC: DFS subanalyses from the C-POST trial
Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses exploratory analyses from the C-POST trial (NCT03969004) evaluating adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiotherapy. Disease-free survival (DFS) benefit with cemiplimab was consistent across all high-risk nodal and non-nodal disease features, and was maintained regardless of the interval between prior radiotherapy completion and study randomization. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the cemiplimab trial was a phase 3 trial of adjuvant cemiplimab in high-risk cutaneous SCC, which found a very significant benefit with cemiplimab compared to placebo, has a ratio of 0.32. One of the significant eligibility criteria was that each patient had to have one or more high-risk clinical pathologic criteria, and they could be nodal or non-nodal. So the nodal criteria included a disease that was a nodal disease that was at least two centimeters of extra capsular extension or more than three nodes, and there were several non-nodal criteria as well...
So the cemiplimab trial was a phase 3 trial of adjuvant cemiplimab in high-risk cutaneous SCC, which found a very significant benefit with cemiplimab compared to placebo, has a ratio of 0.32. One of the significant eligibility criteria was that each patient had to have one or more high-risk clinical pathologic criteria, and they could be nodal or non-nodal. So the nodal criteria included a disease that was a nodal disease that was at least two centimeters of extra capsular extension or more than three nodes, and there were several non-nodal criteria as well. So in this analysis that we presented at ASCO this year, we looked at each individual criterion to see if they were significant in terms of benefit from cemiplimab. And we found that each of the nodal and all of the non-nodal criteria were significant with an advantage for cemiplimab compared to placebo.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
